Novavax, Inc. (NASDAQ:NVAX) price on Wednesday, April 17, fall -2.51% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.89.
A look at the stock’s price movement, the close in the last trading session was $3.99. The beta value (5-Year monthly) was 1.60. Turning to its 52-week performance, $11.36 and $3.53 were the 52-week high and 52-week low respectively. Overall, NVAX moved -24.32% over the past month.
Novavax, Inc.’s market cap currently stands at around $544.41 million, with investors looking forward to this quarter’s earnings report slated for May 07, 2024 – May 13, 2024.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that NVAX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
NVAX’s current price about -14.24% and -16.79% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 30.15, while 7-day volatility ratio is 5.02% and 5.06% in the 30-day chart. Further, Novavax, Inc. (NVAX) has a beta value of 1.64, and an average true range (ATR) of 0.27.
If we refocus on Novavax, Inc. (NASDAQ:NVAX), historical trading data shows that trading volumes averaged 7.51 million over the past 3 months. The company’s latest data on shares outstanding shows there are 139.51 million shares.
The 4.94% of Novavax, Inc.’s shares are in the hands of company insiders while institutional holders own 56.87% of the company’s shares. Current price change has pushed the stock -18.96% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NVAX stock continues to rise going into the next quarter.
